Why the study?
Clinical trials evaluating ACEis, ARBs, and BBs for cancer-related cardiotoxicity focused on ejection fraction declines without examining long-term, hard clinical endpoints.
Does the use of ACEis/ARBs, CCBs, or diuretics compared to beta blockers affect the risk of cardiac events in postmenopausal women with and without cancer?
Population
56,997 Women's Health Initiative participants free of CVD receiving antihypertensive treatment
Comparison
ACEis/ARBs, CCBs, or diuretics vs BBs, in women with and without cancer
Design
Prospective cohort study
Authors
Loading...
Should not yet change antihypertensive selection in cancer survivors; leaves open causal confirmation in randomized trials.
Does the use of ACEis/ARBs, CCBs, or diuretics compared to beta blockers affect the risk of cardiac events in postmenopausal women with and without cancer?
In postmenopausal women with a history of cancer, beta blockers may be associated with a lower risk of long-term cardiac events compared to ACE inhibitors or ARBs.
Reding et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: